DelveInsight's "Adrenoleukodystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
Adrenoleukodystrophy: Disease Overview
Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands.
Know more about report offerings: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Adrenoleukodystrophy Epidemiology Analysis
The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented into:
- Total Adrenoleukodystrophy Prevalent Population
- Gender-specific Adrenoleukodystrophy Prevalence
- Gender-specific Diagnosed Adrenoleukodystrophy Prevalence
- Type-specific Diagnosed Prevalence of ALD in Males
However, rare, Adrenoleukodystrophy is a devastating disease and has no cure.
Request for free sample pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market
Adrenoleukodystrophy treatment market comprises of general supportive care and symptomatic treatment, primarily managed by hormone replacement therapy, dietary therapy with Lorenzo’s oil, and Hematopoietic stem cell transplantation.
Adrenoleukodystrophy Market Analysis
The Adrenoleukodystrophy market report provides current treatment practices, emerging drugs, Adrenoleukodystrophy market share of the individual therapies, current and forecasted Adrenoleukodystrophy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Adrenoleukodystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
- The market size for ALD was USD 523.26 million in 2017 for the US.
- The ALD market is driven by key pharma players such as Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, and others are proactively focusing on advancing ALD pipeline, increasing prevalence, and increased R&D in the domain.
- A noticeable growth can be seen in the year 2022 owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
- Lenti D: bluebird bio
- Leriglitazone: Minoryx Therapeutics
- MGTA-456: Magenta Therapeutics
- MD1003: MedDay Pharmaceuticals
- OP-101: Orpheris
- SOM1201: SOM Biotech
Visit to know more: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Table of Contents
1. Key Insights
2. Adrenoleukodystrophy (ALD): Market Overview at a Glance
3. Adrenoleukodystrophy: Disease Background and Overview
4. Epidemiology and Patient Population
5. United States Epidemiology
6. EU5 Epidemiology
7. Japan Epidemiology
8. Current Treatment and Medical Practices
9. Unmet Needs
10. Emerging Therapies
11. Failed Therapy
12. Adrenoleukodystrophy (ALD): 7MM Market Analysis
13. 7MM: Market Outlook
14. United States
15. EU-5 countries
17. Market Drivers
18. Market Barriers
20. DelveInsight Capabilities
22. About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Address:304 S. Jones Blvd #2432
State: New York
Country: United States